What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · LONG · GNLB

Weight-loss drugs fuel a protein powder boom — ride the nutrition trend on Glanbia

The massive popularity of new weight-loss drugs is creating a booming side-business for nutrition companies. People losing weight on these medications are buying huge amounts of protein powder to maintain their muscle, causing Glanbia's stock to rally.

Idea

Millions of people taking GLP-1 weight-loss medications are finding they need extra protein to avoid losing muscle mass alongside the fat. This creates a massive, entirely new customer base for nutrition and protein powder companies. As long as the weight-loss drug megatrend continues, demand for sports nutrition should ride the wave higher, making dips in companies like Glanbia attractive.

Key details

GNLBD1#stock#consumer#trend_following

Community

Upvotes

Views

Copies

Cosigns

News sources

GLP-1 Craze Fuels Protein-Powder Maker Glanbia's Share Rally — Bloomberg

Related ideas

Nvidia tanks $1 trillion as panic selling hits tech — contrarian bounce play on the AI king
WD-40 stock jumps 15% on huge earnings surprise — catch the post-earnings momentum
Nvidia crashes to pre-AI prices while AI demand stays red-hot — contrarian bounce play on NVDA

GNLB trade ideas
Latest market news